Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Xl-019. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 18/20 | 1.00 |
| ▸ | JAK3 | P52333 | 13/20 | 1.00 |
| ▸ | JAK1 | P23458 | 6/20 | 1.00 |
| ▸ | TYK2 | P29597 | 4/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | IKBKB | O14920 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xl-019 SCHEMBL4379072 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| Xl-019 SCHEMBL29366461 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| Xl-019 SCHEMBL4382715 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| Xl-019 SCHEMBL30925304 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378445 | 0.97 | JAK2 (0.95) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378440 | 0.97 | JAK2 (0.95) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4375174 | 0.96 | JAK2 (0.93) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL8239823 | 0.93 | JAK2 (0.87) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4378206 | 0.91 | JAK2 (0.84) | JAK2JAK3JAK1TYK2PDGFRB | |
| SCHEMBL4382090 | 0.91 | JAK2 (0.84) | JAK2JAK3JAK1TYK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | claimed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | claimed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4132524-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | Aclaris Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115666566-A | Oral compositions of MK2 pathway inhibitors for the treatment of immune conditions | 阿克拉瑞斯治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885JAK1 1/4885 |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | MAPKAPK2, MAP3K2, MAPK9 | JAK2 395/4885JAK3 328/4885JAK1 297/4885 |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | JAK2 1137/4885JAK3 1645/4885JAK1 1304/4885 |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | JAK2 1137/4885JAK3 1645/4885JAK1 1304/4885 |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | JAK2 1137/4885JAK3 1645/4885JAK1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.